Advancing Therapeutic Innovation in Sexual Medicine
Sensory
Restoration
Advancing a novel approach to restoring sensation and treatment adherence.
Initial Focus
Antidepressant-Associated Sexual Dysfunction (AASD)
A Persistent,
Untreated
Side Effect.
Sexual side effects are a leading cause of antidepressant discontinuation, driving a 50% higher relapse risk in patients.
- Reduced genital sensation
- Blunted arousal response
- Delayed or absent orgasm
Up to 70%
Of patients on antidepressants report treatment-emergent sexual dysfunction.
$326B
Annual economic burden of untreated depression & non-adherence.
Peer-Reviewed Foundation
The
Observation.
Published in Sexual Medicine
Oxford University Press | Peer Reviewed | March 2026
Sexual Medicine Journal
Peer-reviewed analysis identified a recurring pattern of enhanced sensation, arousal, and orgasmic function. These effects are inconsistent with the compound's expected sedative profile and warrant further investigation.
Publication Details
From sedation to stimulation: anecdotal case reports of enhanced sexual arousal...
Authors: Melitzsa Pascale Regis, BS & James G. Pfaus, PhD
Published: March 2026 | Oxford University Press
Consistent Pattern
The signal was consistently reported across multiple domains: sensation, arousal, and orgasmic response.
Differentiated Observation
One published case report described the apparent reversal of antidepressant-associated sexual dysfunction, an observation warranting prospective investigation.
The Competitor Gap
Unlike PDE5 inhibitors, which primarily address vascular function, Paradoxica is investigating a differentiated approach focused on sensory dysfunction.
Defensible Estate
Intellectual Property
A provisional patent has been filed covering a broad set of claims independent of any single compound or mechanism.
Compound-Independent
Claims cover any agent that induces the phenotype, not DPH specifically. Future NCEs identified may be included.
Mechanism-Independent
Scope does not depend on validating a specific biological pathway. The phenotype framework is the anchor.
Combination Therapies
Includes co-formulating a phenotype-inducing agent with an SSRI as a single unit-dose.
The Operators & Experts
Leadership &
Scientific Advisor.
Scientific guidance provided by Dr. James G. Pfaus, PhD, co-author of the foundational publication underlying Paradoxica Therapeutics' therapeutic hypothesis.
Melitzsa Regis, BS
Founder & CEO
Founder, CEO, and co-author of the first peer-reviewed publication describing the sensory-restoration phenotype. Developed the company's intellectual property strategy and validation roadmap supporting Paradoxica's therapeutic platform.
Dr. James G. Pfaus, PhD
Scientific Advisor
Professor and internationally recognized researcher in sexual neuropharmacology and sexual behavior. His work has been cited thousands of times and has helped shape modern understanding of sexual motivation, reward, and neurobehavioral mechanisms.
Milestones & Execution
Development Roadmap
Progressive de-risking of the sensory-restoration hypothesis through phased validation and execution.
Completed Milestones
- Peer-Reviewed Observation Identified
- Peer-Reviewed Publication Published in Sexual Medicine
- Paradoxica Therapeutics Founded
- Provisional Patent Application Filed
- Scientific Advisor Secured (Dr. James G. Pfaus, PhD)
Current Stage
- Validation Study Planning
- Strategic Partner Outreach
- Real-World Data Analysis
Future Milestones
- Prospective Clinical Validation Study
- Independent Replication of Findings
- Lead Program Definition
- Expanded Intellectual Property Portfolio
- Regulatory Strategy Development
- Preparation for Clinical Development
- Strategic Partnerships & Licensing
Research-Stage. Evidence-First.
From Observation
to Validation
Paradoxica is built on a published clinical observation: a recurring sensory-restoration phenotype documented in the peer-reviewed literature. Our work now is to characterize it and define the controlled studies needed to validate it.
Published Foundation
A peer-reviewed case series in Sexual Medicine (Oxford University Press) documenting the observed phenotype.
Defensible IP
A filed provisional patent anchored to the phenotype, independent of any single compound or mechanism.
A Defined Path
A clear validation roadmap toward reproducing the signal under controlled conditions and characterizing responders.